ENSPRYNG
ENSPRYNG is an interleukin-6 (IL-6) receptor antagonist indicated for the treatment of neuromyelitis optica spectrum disorder (NMOSD). It is specifically approved for use in adult patients who are anti-aquaporin-4 (AQP4) antibody positive. The medication provides a targeted therapeutic option for managing this specific autoimmune condition in the indicated patient population.
How ENSPRYNG Works
Satralizumab-mwge functions by binding to both soluble and membrane-bound interleukin-6 (IL-6) receptors. This action is presumed to inhibit IL-6-mediated signaling, which is the biological pathway through which the drug exerts its therapeutic effects. While the precise mechanism in NMOSD is unknown, the drug acts as an antagonist to block these specific receptors.
Details
- Status
- Prescription
- First Approved
- 2020-08-14
- Routes
- INJECTION
- Dosage Forms
- INJECTABLE
ENSPRYNG Approval History
What ENSPRYNG Treats
1 indicationsENSPRYNG is approved for 1 conditions since its original approval in 2020. These indications span multiple therapeutic areas including oncology, immunology, and more.
- Neuromyelitis Optica Spectrum Disorder
ENSPRYNG Target & Pathway
ProTarget
A cytokine involved in inflammation and immune regulation. Elevated IL-6 drives inflammation in rheumatoid arthritis and is linked to cytokine release syndrome. Blocking IL-6 or its receptor reduces inflammatory responses in autoimmune conditions.
ENSPRYNG Competitors
Pro1 other drug also targets IL-6. Compare mechanisms, indications, and trial activity.
Competitors share the same molecular target (IL-6). Earlier expiry dates signal biosimilar/generic opportunities.
Active Pipeline
Ongoing clinical trials by development phase
Key Completed Trials
Completed studies with published results, ranked by significance
Trial Timeline
Full development history with FDA approval milestones
Understanding FDA Approval Types
| Count | Type | What it means |
|---|---|---|
| - | ORIG | Original approval - drug first enters market |
| - | SUPPL - Efficacy | New indication (new disease/condition approved) |
| - | SUPPL - Labeling | Label text changes (warnings, dosing updates) |
| - | SUPPL - Manufacturing | Production changes (new facility) |
| - | SUPPL - Chemistry | Formulation changes (new dosage strength) |
Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.
ENSPRYNG FDA Label Details
ProIndications & Usage
FDA Label (PDF)ENSPRYNG is indicated for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adult patients who are anti-aquaporin-4 (AQP4) antibody positive. ENSPRYNG is an interleukin-6 (IL-6) receptor antagonist indicated for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adult patients who are anti-aquaporin-4 (AQP4) antibody positive.
Want competitive intelligence?
See who's developing similar drugs and track their progress
Data Sources
Data sourced from official FDA and NIH databases. Click links to verify on original sources.